Yashiro Daisuke, Kuwatsuru Yoshiki, Toei Hiroshi, Udagawa Takeshi, Okada Shingo, Kato Hitomi, Saito Naoko, Kuwatsuru Ryohei
Department of Radiology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Center for Promotion of Data Science, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
J Clin Med. 2025 Jul 25;14(15):5276. doi: 10.3390/jcm14155276.
To evaluate the diagnostic performance of non-enhanced MRA in detecting intratumoral aneurysms in renal AML, using digital subtraction angiography (DSA) as the reference standard. Fourteen female patients (mean age, 39 years; range, 21-57 years) who received prophylactic transcatheter arterial embolization (TAE) for non-hemorrhagic renal AML(s) between July 2010 and September 2018 were included in this study. All received a non-enhanced MRA scan prior to TAE. Non-enhanced MRA images were obtained using the flow-in technique with three-dimensional balanced steady-state free precession (SSFP). The MRA and DSA images were jointly evaluated by three radiologists. In this study, significant aneurysms were defined as aneurysms with a diameter of 3 mm or more within the renal AML. The MRA images assessed the number and location of significant aneurysms. The DSA images were used as the reference standard. DSA identified 30 significant aneurysms in eight kidneys; MRA identified 26, giving a sensitivity of 87%. There were no false positives, resulting in a specificity of 100%. Flow-balanced SSFP MRA is effective in detecting significant aneurysms in renal AML and could be a viable alternative for patient follow-up.
以数字减影血管造影（DSA）为参考标准，评估非增强磁共振血管造影（MRA）检测肾血管平滑肌脂肪瘤（AML）瘤内动脉瘤的诊断性能。本研究纳入了2010年7月至2018年9月期间因非出血性肾AML接受预防性经导管动脉栓塞术（TAE）的14例女性患者（平均年龄39岁；范围21 - 57岁）。所有患者在TAE前均接受了非增强MRA扫描。使用流入技术和三维平衡稳态自由进动（SSFP）获得非增强MRA图像。MRA和DSA图像由三位放射科医生共同评估。在本研究中，显著动脉瘤定义为肾AML内直径3 mm或更大的动脉瘤。MRA图像评估显著动脉瘤的数量和位置。DSA图像用作参考标准。DSA在8个肾脏中识别出30个显著动脉瘤；MRA识别出26个，敏感性为87%。无假阳性结果，特异性为100%。流动平衡SSFP MRA在检测肾AML中的显著动脉瘤方面有效，并且可能是患者随访的可行替代方法。
